Предсердное электрофизиологическое ремоделирование у пациентов фибрилляцией предсердий и артериальной гипертензией без структурных изменений сердца
Диссертация
Метод изучения особенностей предсердной рефрактерности и проведения у больных фибрилляцией предсердий и артериальной гипертензией без структурных изменений сердца позволяет оценить как степень выраженности электрофизиологического ремоделирования, так и определить тактику лечения. Разработаны рекомендации по использованию прямого блокатора ренина у пациентов пароксизмальной формы фибрилляции… Читать ещё >
Список литературы
- Бокерия Л. А., Голухова Е. 3., Кочладзе Н. Г. и др. Прогностическое и клиническое значение маркеров ремоделирования предсердий при фибрилляции предсердий. Анналы аритмологии. 2004−1:71−77.
- Бокерия Л. А., Ермоленко М. Л., Базаев В. А. и др Механизмы возникновения и поддержания фибрилляции предсердий: экспериментальное обоснование и. клиническое значение для выбора метода лечения. Анналы аритмологии. 2005−2:17−25.
- Бокерия Л.А., Махалдиани З. Б., Журавлев В. А. Современное состояние проблемы медикаментозного лечения фибрилляции предсердий. Анналы аритмологии-2006:5−17.
- Бунин Ю. А. Лечение фибрилляции и трепетания предсердий Лечащий врач. 2002−8:4−8.
- Голицин С.П. Рецидивирование фибрилляций предсердий после электрической кардиоверсии Журн. Сердечная недостаточность. 2003−1:51−52.
- Голухова Е.З. Мерцательная аритмия: восстановление ритма против контроля его частоты. Быть здоровым и богатым или бедным и больным? Анналы аритмологии. 2005−2- ч. 1:46−49.
- Зонов О. А., Ильиных И.И." Коковин Н. В. и др. Анализ факторов, влияющих на эффективность электрической, кардиоверсии при постоянной форме мерцательной аритмии у больных артериальной гипертензией Вятский мед. вестн.1999−3:С. 26−28.
- Искандеров Б.Г., Рахматуллов Ф. К. Структурные и электрофизиологические показатели функции сердца при пароксизмальной мерцательной аритмии. Терапевт, арх.2001- 12:5256.
- Истомина Т. А., Говша Ю. А., Воронин И. М., Сметнев А. С. Левое и правое предсердие в генезе пароксизмальной формы мерцательной аритмии Вестн. РУДЫ. 2000−1:96−99.
- Канорский С.Г., Зингилевский К. Б. Восстановление функции левого предсердия после кардиоверсии мерцательной аритмии: роль некоторых клинических и эхокардиографических факторов Кардиология. 2002−2:54−58.
- Кушаковский М.С. Фибрилляция предсердий (причины, механизмы, клинические формы, лечение и профилактика) Санкт-Петербург. :Фолиант1 999.-70.
- Мазур Н. А. Фибрилляция предсердий. Клин, фармакология и терапия. 2003−3:32−35.
- Мерцательная аритмия. Под редакцией С. А. Бойцова. Санкт-Петербург. 2001
- Ревишвили А. Ш., Рзаев Ф. Г., Имнадзе Г. Г. и др. Легочные вены -пусковой фактор и возможный субстрат пароксизмальной формы фибрилляции^ предсердий Клин, физиология кровообращения. 2005:1:34−38.
- Сулимов В.А. Медикаментозная терапия фибрилляции- предсердий: настоящее и будущее. Кардиология. 1999−7:69−75.
- Татарский Б. А. Тактика ведения больных с пароксизмальной фибрилляцией предсердий. Сердце. 2002−2:83−87.
- Татарский Б. А. Электрическая наружная кардиоверсия при лечении пароксизмальной фибрилляции предсердий Вестн. аритмологии. 2000−19:95−99.
- Allessie М, Boyden Р, Camm A. et all. Pathophysiology and prevention of atrial fibrillation. Circulation 2001−103:769−777
- Atend L, Nattel S, Ehrlich J. Atrial fibrillation. In: Zipes DP, Jalife J. eds. Cardiac Electrophysiology: From Cell to Bedside. 4th ed. Saunders: Philadelphia- 2004:512−521.
- ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation. A report of the American College of Cardiology/American Heart Association. Task Force on practice guidelines and the European Society of
- Cardiology. Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). Europace 2006- 8- 651−745
- Aksnes T, Schmieder R, Kjeldsen S, et al. Impact of new-onset diabetes mellitus on development of atrial fibrillation and heart failure in high-risk hypertension (from the VALUE Trial). Am J Cardiol 2008- 101: 634−8.
- Allessie M, Ausma J, Schotten U. Electrical, contractile and structural remodeling during atrial fibrillation. Cardiovasc Res 2002- 54: 230−46.
- Allessie M. Atrial electrophysiologic remodeling: another vicious circle? J Cardiovasc Electrophysiol 1998−10:178−193.
- Allessie M., Boyden P., Camm A. et all. Pathophysiology of atrial fibrillation. Circulation 2007−108:673−682
- Alp N, Rahman S, Bell J, et al. Randomised comparison of antero-lateral versus antero-posterior paddle positions for DC cardioversion of persistent atrial fibrillation. Int J Cardiol 2000- 75: 211−16.
- Asher C, Miller D, Grimm R et al. Analysis of risk factors for development of atrial fibrillation. Am. J. Cardiol. 1998−82:892−895.
- Atlas S. The renin-angiotensin aldosterone system: pathophysiological role and pharmacologic inhibition. J. Manag. Care Pharm.2007−13(Suppl B):9— 20.
- Aviles R., Martin D. et al. Inflammation as a risk factor for atrial fibrillation Circulatiomo 2003−108:3006−3010.
- Benajmim E., Levy D., Vaziri S. et al. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study JAMA 1994.171:840−44.
- Benjamin E., Wolf P., D’Agostino R. et al. Impact of atrial fibrillation on risk of death: the Framingham study. Circulation 1999−98:946−52.
- Boos C., Anderson R.A. Is atrial fibrillation an inflammatory disorder? Eur. Heart J.2006- 27:136−149.
- Borzecki A, Bridgers D, Liebschutz J. et al. Racial differences in the prevalence of atrial fibrillation among males. J Natl Med Assoc 2008- 100: 237−44.
- Botto G, Politi A, Bonini W, et al. External cardioversion: role of paddle position on technical efficacy and energy requirements. Heart 1999- 82: 726−30
- Brundel B, Henning R- Kampinga H. et al. Molecular mechanisms of remodeling in human atrial fibrillation. Cardiovasc Res 2002- 54: 315−24.
- Casaclang-Verzosa G, Gersh B, Tsang T. Structural and functional remodeling of the left atrium: clinical and therapeutic implications for atrial fibrillation. J Am Coll Cardiol 2008- 51:1−11.
- Chen S, Tai C, Yu W et al. Right atrial focal atrial fibrillation: electrophysiologic characteristics and radiofrequency catheter ablation. J Cardiovasc Electrophysiol 1999−10:328 -35.
- Chen S, Tai C, Yu W. et al. Atrial fibrillation: electrophysiologic characteristics and radiofrequency catheter ablation. J Cardiovasc Electrophysiol 2002- 10:328 -35.
- Choj. T. LV hypertrophy and AF. Hypertension 2003- 41:218−23
- DanserA. Renin, prorenin, and the putative prorenin receptor. Hypertension 2005- 46: 1069−76
- Danser A. Renin, prorenin, and the putative prorenin receptor. Hypertension 2005- 46: 1069−76.
- Daoud E, Bogun F, Goyal R, et al. Effect of atrial fibrillation on atrial refractoriness in humans Circulation 1996−94:1600−1606.
- Daoud EG, Weiss R, Bahu M et al. Effect of an irregular ventricular rhythm on cardiac output. Am. J. Cardiol. 1996−78:1433−1436.
- De Ponti R., Tritto M., Zardini M. et al. Altered pattern in electroanatomical maps on sinus rhythm in patients with paroxysmal idiopathic atrial fibrillation. European Heart Journal Vol 22, Abstr.Suppl. August/September 2001, page 339
- Dorian P, Paquette M, Newman D et al. Quality of life improves with treatment in the Canadian Trial of Atrial Fibrillation. Am. Heart J. 2002−143:984−990.
- Eckstein J, Verheule S, de Groot N, et al. Mechanisms of perpetuation of atrial fibrillation in chronically dilated atria. Prog Biophys Mol Biol 2008- 97:435−51.
- Elhendy A, Gentile F, Khandheria BK, et al. Predictors of unsuccessful electrical cardioversion in atrial fibrillation. Am J Cardiol 2002- 89: 83−6.
- Ezekowitz M, James K, Nazarian S et al. For the Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. Silent cerebral infarction in patients with nonrheumatic atrial fibrillation. Circulation 1995−92:2178−2182.
- Fareh S, Villemaire C, Nattel S. Importance of refractoriness heterogeneity in the enhanced vulnerability to atrial fibrillation induction caused by tachycardia-induced atrial electrical remodeling Circulation 1998−98:2202−2209.
- Farina E, Magni E, Ambrosisni F et al. Neurophysiological deficits in asymptomatic atrial fibrillation. Acta Neurol. Scand. 1997−96:310−316.
- Fauchier L, Pierre B, de Labriolle A, et al. Antiarrhythmic effect of statin therapy and atrial fibrillation a meta-analysis of randomized controlled trials. J Am Coll Cardiol 2008- 51: 828−35.
- Feinberg W, Blackshear JL, Laupacis A et al. Prevalence, age distribution, andr gender of patients with atrial fibrillation. Analysis and implications. Arch.Intern.Med. 1995- 155:469−473.
- Feinberg W., Seeger J., Carmody R. et al. Asymptomatic cerebral infarction inpatients with atrial fibrillation. Circulation 1988−19:955−957.
- Fetsch T, Bauer P, Engberding R. et al. Prevention of Atrial Fibrillation after Cardioversion Investigators. Prevention of atrial fibrillation after cardioversion: results of the PAFAC trial. Eur Heart J 2004- 25: 1385−94.
- Fisher N, HoUenberg N. Renin inhibition: whar are the therapeutic opportunities?! Am Soc Nephrol 2005−16:592−9
- Friberg J, Scharling H, Gadsboll N, et al. Sex-specific increase in the prevalence of atrial fibrillation (The Copenhagen City Heart Study).Am J Cardiol 2003−92:1419−23.
- Frishman W, Heiman M, Karpenos A et al. Twenty-four-hour ambulatory electrocardiography in elderly subjects: prevalence of various arrhythmias and prognostic implications (report from the Bronx Longitudinal Aging Study). Am. Heart J. 1996−132:297−302.
- Furberg C, Psaty B, Manolio T et al. Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study). Am. J. Cardiol. 1994−74:236−241.
- Futterman, L., Lemberg L. Atrial Fibrillation: Am J Crit Care 2005- 14:438 440
- Gami A., Hodge D, Herges R, et al. Obstructive sleep apnea, obesity, and the risk of incident atrial fibrillation. J Am Coll Cardiol 2007- 49: 565−71.
- Gaspo R., Bosch R., Talajic M. et al. Functional' mechanisms underlying tachycardia-induced sustained atrial fibrillation in, a chronic dog model Circulation 1997−96:4027−4035.
- Gerstenfeld E., Guerra P., Sparks P. et al. Clinical outcome after radiofrequency catheter ablation of focal atrial fibrillation triggers. J. Cardiovasc. Electrophysiol. 2001−12:900−908
- GISSI-AF Investigators, Disertori M, Latini R, et al. Valsartan for prevention of recurrent atrial fibrillation. N Engl J Med 2009- 360: 1606−17.
- Goette A, Bukowska A, Lendeckel U. et al. Angiotensin II receptor blockade reduces tachycardia-induced atrial adhesion molecule expression. Circulation 2008- 117: 732−42.
- Goette A, Honeycutt C, Langberg J. Electrical remodeling in atrial fibrillation: Time course and mechanisms. Circulation 1996−94:2968−2974.
- Gosselink A, Crijns HJ, van den Berg M, et al. Functional capacity before and after cardioversion of atrial fibrillation: a controlled study. Br Heart J 1994- 72: 161−6.
- Grogan M, Smith HC, Gersh B. et al. Left ventricular dysfunction due to atrial fibrillation in patients initially believed to have idiopathic dilated cardiomyopathy. Am. L. Cardiol. 1992−69:1570−1573.
- Hadian D., Jayachandran V., Groh W. et al. Short-Term Rapid5 Atrial Pacing Produces Electrical". Remodeling of the Sinus Node Function in Humans. Suppliment to Journal • of the American College of Cardiology, March 6,2002,Vol.39,Issue5,Suppl.A.
- Haissaguerre M, Hocini M, Takahashi Y. et al. Impact of catheter ablation of the coronary sinus on paroxysmal or persistent atrial fibrillation J Cardiovasc Electrophysiol 2007−18:314−321.
- Haissaguerre M, Jais P, Shah D et al. Electrophysiological end point for catheter ablation- of atrial fibrillation initiated from multiple pulmonary venous foci. Circulation 2000−101:1409−1417.
- Haissaguerre M, Jais P, Shah- D. et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins N Engl J Med 1998−339:659−666.
- Hanna N, Cardin S, Nattel S. Differences in atrial versus ventricular remodeling in dogs with ventricular tachypacing-induced congestive heart failure. Cardiovasc Res 2004−63:236−244.
- Healey J, Baranchuk A, Crystal E, et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J Am Coll Cardiol 2005- 45: 1832−9.
- Heeringa J, van der Kuip D, Hofman A, et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J 2006- 27: 949−53.
- Hindricks G, Piorkowski C, Tanner H et al. Perception of atrial fibrillation before and after radiofrequency catheter ablation: Relevance of asymptomatic arrhythmia recurrence. Circulation 2005- 112:307−313.
- Hoit B, Shao Y, Gabel M. et al. Left atrial mechanical and biochemical adaptation to pacing induced heart failure. Cardiovasc Res 1995- 29: 469— 74.
- Hsu L, Jais P, Keane D et al. Atrial fibrillation originating from persistent left superior vena cavai Circulation 2004- 109:828 -32.
- Huang Y, Wongamorntham S, Kasting J. et al. Renin increases mesangial cell transforming growth factor-betal and matrix proteins through receptor-mediated, angiotensin Il-independent mechanisms. Kidney Int 2006- 69:1 OS-IS.
- Jacquemet V., Virag N., Henriquez C. et al. Study of initiation and perpetuation of atrial* fibrillation in a computer model of human atria based on magnetic resonance images. European Heart Journal Vol 4, Abstr.Suppl. August 2002, page46.
- Jais P, Haissaguerre M, Shah D et al. A focal source of atrial fibrillation treated by discrete radiofrequency ablation. Circulation-1997−95:572−6.
- Jais P, Hocini M, Macle L, et al. Distinctive electrophysiological properties of pulmonary veins in patients with atrial fibrillation Circulation 2003−106:2476−2485.
- Jais P, Hocini M, Sanders P et al. Long-term evaluation of atrial fibrillation ablation guided by non-inducibility. Heart Rhythm 2006−3:140−145.
- Kannel W., Wolf P., Benjamin E. et al. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol. 1998−82:2N-9N.
- Kato T, Yamashita T, Sagara K, et al. Progressive nature of paroxysmal atrial fibrillation. Observations from a 14-year follow-up study. Cire J 2004- 68: 568−72.
- Kempster PA, Gerraty RP, Gates PC. Asymptomatic cerebral infarction in patients with chronic atrial fibrillation. Stroke. 1988−19:955−957.
- Kerr C, Boone J, Connolly S et al. Follow-up of atrial fibrillation: the initial experience of the Canadian Registry of Atrial Fibrillation. Eur. Heart J. 1996- 17 (SuppLC):48−51.
- Kirchhof P. New antiarrhythmic drugs and new concepts for old drugs. In Zipes DP, Jalife J (eds.) 2008. Cardiac Electrophysiology: From Cell to Bedside, in press. Futura.
- Kirchhof P, Fetsch T, Hanrath P, et al. Targeted pharmacological reversal of electrical remodeling after cardioversion—rationale and design of the Flecainide Short-Long (Flec-SL) trial. Am Heart J 2005- 150: 899.
- Kirchhof P, Fortmuller L, Waldeyer C, et all Drugs that interact with cardiac electro-mechanics: old' and new targets for treatment: Prog Biophys Mol Biol 2008- 97: 497−512.
- Konings K, Smeets J, Penn O, et al. Configuration of unipolar atrial electrograms during electrically induced atrial fibrillation in humans Circulation 1997−95:1231−1241.
- Kopecky S, Gersh B, McGoon M. et al. The natural history of lone atrial fibrillation. A population-based study over three decades. N Engl J Med 1987−317:669−74.
- Kopecky S., Gersh B., McGoon M. et al. The natural history of lone atrial fibrillation. N. Engl. J. Med. 1994−325:501−508.
- ICorantzopoulos P, Kolettis T, Siogas K. Atrial fibrillation and electrical remodeling: the potential role of inflammation and oxidative stress. Med Sei Monit 2003- 9: RA225−9.
- Kourliouros A, Savelieva I, Jahangiri M, et al. Current concepts in the pathogenesis of atrial fibrillation. Am Heart J'2009- 157: 243−52.
- Krahn A., Manfreda J., Tate R. et al. The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. Am J Med 1995−98:476−84.
- Kulbertus H, de Leval-Rutten F, Bartsch P et al. Atrial fibrillation in elderly, ambulatory patients. In: Kulbertus HE, Olsson SB, Schlepper M, eds. Atrial fibrillation. Moelndal. AB Haessle. 1982:148−157.
- Kumagai K, Nakashima H, Urata H, et al. Effects of angiotensinJI type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation. J Am Coll Cardiol 2003- 41: 2197−204.
- Kumagai K, Ogawa M, Noguchi H, Yasuda T, Nakashima H, Saku K. Electrophysiologic properties of pulmonary veins assessed using a multielectrode basket catheter J Am Coll Cardiol 2004−43:2281−2289.
- Kusumoto W., Raitt M. Atrial Electrical Remodeling Following Cardioversion of Atrial Fibrillation in Humans. ACC 2001 50th Annual Scientific Session March 18−20,2001. V.37.N2,Suppl. A.1A-648A.
- Lafuente-Lafuente C, Mouly S, Longas-Tejero M, et al. Antiarrhythmic drugs for maintaining sinus rhythm after cardioversion of atrial fibrillation: a systematic review of randomized
- Lazar S, Dixit S, Marchlinski F. Presence of left-to-right atrial frequency gradient in paroxysmal but not persistent atrial fibrillation in humans Circulation 2004- 110:3181−3186.
- Levy S, Maarek M, Coumel P et al. Characterization-of different subsets of atrial fibrillation in general practice in France: the ALFA study. The College of French Cardiologists. Circulation 1999−99:3028−3035.
- Levy S, Coumel’P: Characterization of different subsets of atrial fibrillation •in general practice. Circulation 2005−105:2065−74.
- Li D, Shinagawa K, Pang L, et al. Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure. Circulation 2001- 104: 2608−14.
- Lip G, Zarifis J, Beevers M. et al. Ambulatory blood pressure monitoring in atrial fibrillation. Am J Cardiol 1996- 78: 350−3.
- Liu L, Nattel S. Differing sympathetic and vagal effects on atrial fibrillation in dogs: role of refractoriness heterogeneity. Am J Physiol 1997- 273(2 Pt 2): H805-H816.
- Liu S., Hertervig E., Yuan S. et al. Use of electroanatomic mapping to delineate transseptal atrial condaction in patients with paroxysmal atrial fibrillation. European Heart Journal Vol 22, Abstr. Suppl. August 2001, page 603.
- Lloyd-Jones D, Wang T, Leip E et al. Lifetime risk for development of atrial fibrillation: the Framingham heart study. Circulation 2004−110:1042−1046.
- Madrid A, Bueno M, Rebollo J et al. Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study. Circulation 2002- 106:331- 6.
- Maisel W, Stevenson L. Atrial fibrillation in heart failure: epidemiology, pathophysiology and rationale for therapy. Am. J.Cardiol. 2003 -91:2D-8D.
- Mandapati R, Skanes A, Chen J. .et al. Stable microreentrant sources as a mechanism of atrial fibrillation. Circulation 2000- 101:194 -199.
- Markides V., Schilling R., Chow A. et al. A left atrial line of critical' to initiation of atriab fibrillation" triggered by focal mechanism: insight from non-contact mapping. European Heart Journal Vol' 22- Abstr. Suppl. August 2001', page 360:
- Miller J., Zipes D. Management of the patient with cardiac arrhithmias. A textbook of cardiovascular medicine. Philadelphia: W. B. Saunders company. 2001- 731−736.
- Miyasaka Y, Barnes M, Bailey K, et al. Mortality trends in patients ' diagnosed with first atrial fibrillation: a 21-year community-based-study. J
- AmColL Cardiol*2007- 49: 986−92.
- Miyasaka’Y, Barnes M, Gersh B, et al. Secular trends in incidence of atrial fibrillationan* Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation 2006- 114: 119−25.
- Morillo C, Klein G^ Jones D. Chronic rapid atrial pacing structural, functional, and electrophysiological characteristics of a new model of sustained atrial fibrillation. Circulation 1995−91:1588−1595
- Nabauer M, Gerth A, Limbourg T, et al. The Registry of the German Competence NETwork on Atrial Fibrillation: Patient characteristics and initial management. Europace 2008- under revision.
- Nademanee K, McKenzie J, Kozar E et al. A new approach for catheter ablation of atrial fibrillation: mapping of the electrophysiologic substrate. J. Am. Coll. Cardiol. 2004−43:2044−2053.
- Nattel S, Burstein B, Dobrev D. Atrial remodeling and atrial fibrillation: mechanisms and implications. Circ Arrhythm Electrophysiol 2008- 1 :62−73.
- Nattel S. New ideas about atrial fibrillation 50 years on. Nature 2002−415:219−26.
- Neuberg H.R., Schotten U., Ausma J. et al. Atrial remodeling in th. e goat to chronic complete atrioventricular block. European Heart Journal Vol 22, Abstr.Suppl. August 2002, page 138
- Nieuwlaat R, Capucci A, Camm A, et al. Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Siirvey on Atrial Fibrillation: Eur Heart J 2005- 26: 2422−34.
- Oral H, Knight B, Tada H et al. Pulmonary Vein Isolation for Paroxysmal and Persistent Atrial Fibrillation. Circulation 2002- 105- 1077−1081.
- Oral H, Veerareddy S, Good E et al. Prevalence of asymptomatic recurrences of atrial fibrillation after successful radiofrequency catheter ablation. J. Cardiovasc. Electrophysiol. 2004−15:920−924.
- Page R, Kerber R, Russell J, et-ah, for the BiCard Investigators. Biphasic versus monophasic shock waveform for conversion' of atrial fibrillation. J Am Coll Cardiol 2002- 39: 1956−63.
- Page R, Tilsh T, Connolly S et ah Asymptomatic or «silent» atrial fibrillation: Frequency in untreated patients and patients receiving azimilide. Circulation 2003−107:1141−1145.
- Page RL, Wilkinson WE, Clair WK et al. Asymptomatic arrhythmias in patients with symptomatic paroxysmal atrial fibrillation and paroxysmal supraventricular tachycardia. Circulation 1994−89:224−227.
- Pappone C, Santinelli V, Manguso F et al. Pulmonary vein denervation enhances long-term benefit after circumferential ablation for paroxysmal atrial fibrillation. Circulation 2004−109:327−334.
- Pilz B, Shagdarsuren E, WellnerM et ah Aliskiren, a human renin inhibitor, ameliorates cardiac and renal damage in double-transgenic rats. Hypertension 2005- 46 (3): 569−76.
- Piorkowski C, Kottkamp H, Tanner H et al. Value of different follow-up strategies to assess the efficacy of circumferential pulmonary vein ablation for the curative treatment of atrial fibrillation. J. Cardiovasc. Electrophysiol. 2005−16:1286−1292.
- Po S, Li Y, Tang D, et al. Rapid and stable re-entry within the pulmonary vein as a mechanism initiating paroxysmal atrial fibrillation. J Am Coll Cardiol 2005- 45: 1871−7.
- Psaty BM, Manolio TA, Kuller LH, et al. Incidence of and risk factors for atrial fibrillation in older adults. Circulation 1997- 96: 2455−61.
- Ravens U, Cerbai E. Role of potassium currents in cardiac arrhythmias. Europace 2008- 10: 1133−7.
- Redfield M, Kay GN, Jenkins LS et al. Tachycardia-related cardiomyopathy: A common cause of ventricular dysfunction in patients with atrial fibrillation referred for atrioventricular ablation. Mayo. Clin. Proc. 2000−75:790−795.
- Rose G, Baxter PJ, Reid DD et al. Prevalence and prognosis of electrocardiographic findings in middle-aged men. Br. Heart J. 1978−40:636−643.
- Rosenqvist M, Lee MA, Moulinier L et al. Long-term follow-up of patients after transcatheter direct current ablation of the atrioventricular junction. J. Am. Coll. Cardiol. 1990−16:1467−1474.
- Rostock T, Lutomsky B, Steven D, Willems S. The coronary sinus as a focal source of paroxysmal atrial fibrillation: more evidence for the 'fifth pulmonary vein?' Pacing Clin Electrophysiol 2007−30:1027−1031.
- Rostock T, Servatius H, Risius T, et al. Impact of amiodarone on electrophysiologic properties of pulmonary veins in patients with paroxysmal atrial fibrillation J Cardiovasc Electrophysiol 2005−16:39−44.
- Sanders P, Morton J, Davidson N et al. Electrical remodeling of the atria in congestive heart failure: electrophysiological and electroanatomic mapping in humans. Circulation 2003- 108:1461- 8.
- Savelieva I, Camm A. Clinical trends in atrial fibrillation at the turn of the millennium. J Intern Med 2001−250:369−372
- Savelieva I, Camm, AJ. Clinical relevance of silent atrial fibrillation: prevalence, prognosis, quality of life, and management. J. Intervent.Card.Electrophysiol. 2000−4:369−382.
- Savelieva I, Camm J. Anti-arrhythmic drug therapy for atrial fibrillation: current anti-arrhythmic drugs, investigational agents, and innovative approaches. Europace 2008- 10: 647−65.
- Savelieva I, Camm J. Statins and polyunsaturated fatty acids for treatment of atrial’fibrillation. Nat Clin Pract Cardiovasc Med 2008- 5: 30−41.
- Savelieva I, Paquette M, Dorian P et al. Quality of life in patients with silent atrial fibrillation. Heart. 2001−85:216−217.
- Schmieder RE, Kjeldsen SE, Julius S, et al.- VALUE Trial Group. Reduced incidence of new-onset atrial fibrillation with angiotensin II receptor blockade: the VALUE trial. J Hypertens 2008- 26: 403−11.
- Schotten U, Duytschaever M, Ausma J, et al. Electrical and contractile remodeling during the first days of atrial fibrillation go hand in hand. Circulation 2003- 107: 1433−9.
- Schotten U., Allessie M.A. Electrical and contractile remodelling due to atrial fibrillation follow the same time course. European Heart Journal Vol 22, Abstr. Suppl. September 2001, page 550.
- Schumacher B, Luderitz B. Rate issues in atrial fibrillation: Consequences of tachycardia and therapy for rate control. Am. J. Cardiol. 1998−82:29N-36N.
- Schwartzman D, Bazaz R, Nosbisch J. Common left pulmonary vein: a consistent source of arrhythmogenic atrial ectopy. J Cardiovasc Electrophysiol 2004−15:560−6.
- Steven D, Rostock T, Lutomsky B et al. What is the real atrial fibrillation burden after catheter ablation of atrial fibrillation? A prospective rhythm analysis in pacemaker patients with continuous atrial monitoring. Eur. Heart J. 2008−29:1037−1042.
- Stevenson IH, Teichtahl H, Cunnington D, et al. Prevalence of sleep disordered breathing in paroxysmal and persistent’atrial fibrillation patients-with normal left’ventricular function. Eur Heart J 2008- 29: 1662−9:
- Stewart S, Hart C, Hole D et al. A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. Am J Med 2002- 113:359−64.
- The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators: A comparison of rate control and rhythm control in. patients with atrial fibrillation. N. Engl. J. Med. 2002−347:1825−1833.
- Thrall G, Lane D, Carroll D, et al. Quality of life in patients with atrial fibrillation: a systematic review. Am J Med 2006- 119: el—19.
- Tieleman R, De Langen C, Van Gelder I. et al. Verapamil reduces tachycardia-induced electrical remodeling of the atria Circulation 1997−95:1209−1216.
- Tsang T, Petty G, Barnes M. et al. The prevalence of atrial fibrillation in incident stroke cases and matched population controls in Rochester,
- Minnesota: changes over three decades. J Am Coll Cardiol 2003- 42: 93 100.
- Tveit A, et al. Results from the CAPRAF Study, a Prospective, Randomized, Placebo-Controlled Study. International Journal of Cardiology, 2007−111:30−35.
- Twidale N, Manda V, Nave K et al. Predictors of outcome after radiofrequency catheter ablation of the atrioventricular node for atrial fibrillation and congestive heart failure. Am. Heart J. 1998 (4 Pt 1) — 136:647 657.
- Van Den Berg M, Crijns H, Haaksma J et al. Analysis of vagal effects on ventricular rhythm in patients with atrial fibrillation. Clin Sci 2003−86:531— 5.
- Van den Berg M, Van Veldhuisen D, Crijns H. et al. Reversion of tachycardiomyopathy after p-blocker. Lancet. 1993−341:1667.
- Van Gelder I, Crijns H, Gilst W. et al. Prediction of uneventful cardioversion and maintenance of sinus rhythm from direct-current electrical cardioversion of chronic atrial fibrillation and flutter. Am J Cardiol 1991- 68: 41−6.
- Van Wagoner D, Pond A, Lamorgese M. Atrial L-type Ca2+ currents and human atrial fibrillation Circ Res 1999−85:428−436.
- Van Wagoner D. Oxidative stress and inflammation in atrial fibrillation: role in pathogenesis and potential as a therapeutic target. J Cardiovasc Pharmacol. 2008- 52: 306−13.
- Vardas P, Kochiadakis G, Igoumenidis N. et al. Amiodarone as a first-choice drug for restoring sinus rhythm in patients with atrial fibrillation: a randomized, controlled study. Chest 2000- 117: 1538−45.
- Vasamreddy C, Dalai D, Dong J. et al. Symptomatic and asymptomatic atrial fibrillation in patients undergoing radiofrequency catheter ablation. J. Cardiovasc. Electrophysiol. 2006−17:134−139.
- Verdecchia P, Reboldi G, Gattobigio R, et al. Atrial fibrillation in hypertension: predictors and outcome. Hypertension 2003- 41: 218—23.
- Vidaillet H, Granada J, Chyou P et al. A population-based study of mortality among patients with atrial fibrillation or flutter. Am.J.Med. 2002- 113:365 370.
- Wanahita N, Messerli FH, Bangalore S, et al. Atrial fibrillation and obesity -results of a meta-analysis. Am Heart J 2008- 155: 310−15.
- Wang T, Larson M, Levy D. et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: The Framingham Heart Study. Circulation <2003- 107:2920−2925.
- Watanabe H, Tanabe N, Watanabe T, et al. Metabolic syndrome and risk of development of atrial fibrillation: the Niigata preventive medicine study. Circulation 2008- 117: 1255−60.
- Weigner M, Caulfield T, Danias P et al. Risk for clinical thromboembolism associated with conversion to sinus rhythm in patients with atrial fibrillation lasting less than 48 hours. Ann. Intern. Med. 1997−126:615−620.
- Wijffels M, Kirchhof C, Dorland R, et al. Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. Circulation 1995- 92: 1954−68.
- Wilhelmsen L, Rosengren A, Lappas G. Hospitalizations for atrial fibrillation in the general male population: morbidity and risk factors. J Intern Med 2001- 250: 382−9.
- Williamson B, Man K, Daoud E et al. Radiofrequency catheter modification of atrioventricular conduction to control the ventricular rate during atrial fibrillation. N. Engl. J. Med. 1994−331:910−917.
- Wolf P, Abbott R- Kannel W. Atrial, fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991- 22: 983−8
- Wolf P, Abbott R. Atrial fibrillation as an independent risk factor for stroke. Stroke 1993−20:973−980.
- Wolf P, Abbott R, Kannel W. Atrial fibrillation: a major contributor to stroke in the elderly. The Framingham study. Arch.Intern.Med. 1987−147:1561−1564.
- Wolk R, Kulakowsky P, Karczmarewicz S et al. The incidence of asymptomatic paroxysmal atrial* fibrillation in patients treated with propranolol or propafenone. Int. J. Cardiol. 1996−54:207−211.
- Wongcharoen W, Chen Y, Chen Y. et al. Aging increases pulmonary veins arrhythmogenesis and susceptibility to calcium regulation agents. Heart Rhythm 2007−4:1338−1349.
- Workman A. J., Kane K.A., Rankin A.C. Cellular changes in action potentials and ion currents associatied with chronic atrial fibrillation in humans. European Heart Journal Vol 21, Abstr.Suppl. August/September 2000, page 544
- Wyse D. The Euro Heart* Survey on atrial fibrillation. Eur Heart J. 2005−26(22):2356−7
- Wyse D, Waldo AL, DiMarco J. et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N. Engl. J. Med. 2002−347:1825−1833.
- Yamada H., Kim Y.J., Tabata T. et al. Correlation of Left Atrial Mechanical and Electrical Remodeling Following Short Duration Atrial Fibrillation. Supplement to Jornal of the American College of Cardiology, March 6,2002, Vol.39, Issue 5. Suppl.A.
- Yamashita T, Ogawa S, Aizawa Y et al. Investigation of the optimal treatment strategy for atrial fibrillation. Cire J. 2008- 67(9): 738−741.
- Yu W, Chen S, Lee S. et al. Tachycardia-induced change of atrial refractory period in humans: rate dependency and effects of antiarrhythmic drugs. Circulation. 2006−97:2331−2337.
- Yue L, Feng J, Nattel S et all. Ionic remodeling underlying action potential changes in a canine model of atrial fibrillation. Circ Res. 1997−81:512−525.
- Yue L, Melnyk P, Gaspo R, Wang Z, Nattel S. Molecular mechanisms underlying ionic remodeling in a dog model of atrial fibrillation Circ Res 1999−84:776−784.
- Zacharias A, Schwann TA, Riordan CJ, et al. Obesity and risk of newonset atrial fibrillation after cardiac surgery. Circulation 2005- 112:3247−55.
- Zaman A., Kearney M., Schecter C. et all. Angiotensin-Converting enzyme inhibitors as adjunctive therapy in patients with persistent atrial fibrillation. Am.Heart.J. 2004−147:823−827.